SBFM (Sunshine Biopharma) EBIT: $-6.13 Mil (TTM As of Mar. 2026)


SBFM Sunshine Biopharma Inc SBFM
34 GF Score
Price $2.16
GF Value $7.10
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma EBIT?

Sunshine Biopharma SBFM +0.93% 34 EBIT is $-6.13 Mil as of Mar. 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.10 (Possible Value Trap). The stock has 4 warning signs investors should review.

Sunshine Biopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-1.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.13 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunshine Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 was -37.13%. Sunshine Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -42.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 390.94%.

Sunshine Biopharma  (NAS:SBFM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunshine Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-5.584 * ( 1 - 0% )/( (14.728 + 15.348)/ 2 )
=-5.584/15.038
=-37.13 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=30.079 - 6.228 - ( 9.123 - max(0, 6.444 - 26.854+9.123))
=14.728

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.93 - 5.669 - ( 6.913 - max(0, 5.878 - 24.783+6.913))
=15.348

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunshine Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.584/( ( (1.316 + max(11.503, 0)) + (1.229 + max(12.201, 0)) )/ 2 )
=-5.584/( ( 12.819 + 13.43 )/ 2 )
=-5.584/13.1245
=-42.55 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.46 + 13.472 + 0.799) - (6.228 + 0 + 0)
=11.503

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.012 + 13.168 + 0.69) - (5.669 + 0 + 8.8817841970013E-16)
=12.201

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunshine Biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6.13/-1.568
=390.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma EBIT Related Terms

Sunshine Biopharma EBIT Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma EBIT Chart

Sunshine Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.11 -26.47 -3.97 -5.36 -5.95

Sunshine Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.30 -1.98 -1.02 -1.73 -1.40

SBFM vs SNOA, CTTH, BUDZ: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunshine Biopharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's EV-to-EBIT falls into.


SBFM
34GF Score
Sunshine Biopharma Inc SBFM
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.13 Mil mean?
Sunshine Biopharma (SBFM) has a EBIT of $-6.13 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunshine Biopharma.
Is Sunshine Biopharma's EBIT too high?
Sunshine Biopharma's current EBIT is $-6.13 Mil. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's EBIT compare to SNOA and CTTH?
Sunshine Biopharma's EBIT of $-6.13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sunshine Biopharma. Sunshine Biopharma's current EBIT is $-6.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.16 — trading 69.6% below its estimated fair value. The current EBIT is $-6.13 Mil. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current EBIT is $-6.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.16 is trading 69.6% below its estimated GF Value™ of $7.10. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

  • EBIT: $-6.13 Mil
  • GF Value™: $7.10 vs. price of $2.16 (69.6% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunshine Biopharma Business Description

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFM

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$7.10
GF Value